Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Proliferative and Invasive Colorectal Tumors in Pet Dogs Provide Unique Insights into Human Colorectal Cancer.

Wang J, Wang T, Sun Y, Feng Y, Kisseberth WC, Henry CJ, Mok I, Lana SE, Dobbin K, Northrup N, Howerth EW, Zhao S.

Cancers (Basel). 2018 Sep 14;10(9). pii: E330. doi: 10.3390/cancers10090330.

2.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1498. [Epub ahead of print]

PMID:
30061364
3.

SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma.

Sakthikumar S, Elvers I, Kim J, Arendt ML, Thomas R, Turner-Maier J, Swofford R, Johnson J, Schumacher SE, Alföldi J, Axelsson E, Couto CG, Kisseberth WC, Pettersson ME, Getz G, Meadows JRS, Modiano JF, Breen M, Kierczak M, Forsberg-Nilsson K, Marinescu VD, Lindblad-Toh K.

Cancer Res. 2018 Jul 1;78(13):3421-3431. doi: 10.1158/0008-5472.CAN-17-3558. Epub 2018 May 3.

PMID:
29724721
4.

Immunohistochemical detection of p53, PTEN, Rb, and p16 in canine osteosarcoma using tissue microarray.

Russell DS, Jaworski L, Kisseberth WC.

J Vet Diagn Invest. 2018 Jul;30(4):504-509. doi: 10.1177/1040638718770239. Epub 2018 Apr 9.

PMID:
29629647
5.

Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.

Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC.

BMC Cancer. 2017 Jan 21;17(1):67. doi: 10.1186/s12885-017-3046-6.

6.

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.

Fenger JM, Roberts RD, Iwenofu OH, Bear MD, Zhang X, Couto JI, Modiano JF, Kisseberth WC, London CA.

BMC Cancer. 2016 Oct 10;16(1):784.

7.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.

Harrington BK, Gardner HL, Izumi R, Hamdy A, Rothbaum W, Coombes KR, Covey T, Kaptein A, Gulrajani M, Van Lith B, Krejsa C, Coss CC, Russell DS, Zhang X, Urie BK, London CA, Byrd JC, Johnson AJ, Kisseberth WC.

PLoS One. 2016 Jul 19;11(7):e0159607. doi: 10.1371/journal.pone.0159607. eCollection 2016.

8.

Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

LeBlanc AK, Mazcko C, Brown DE, Koehler JW, Miller AD, Miller CR, Bentley RT, Packer RA, Breen M, Boudreau CE, Levine JM, Simpson RM, Halsey C, Kisseberth W, Rossmeisl JH Jr, Dickinson PJ, Fan TM, Corps K, Aldape K, Puduvalli V, Pluhar GE, Gilbert MR.

Neuro Oncol. 2016 Sep;18(9):1209-18. doi: 10.1093/neuonc/now051. Epub 2016 May 14. Review.

9.

Non-immunosuppressive FTY720-derivative OSU-2S mediates reactive oxygen species-mediated cytotoxicity in canine B-cell lymphoma.

Mani R, Yan R, Mo X, Chen CS, Phelps MA, Klisovic R, Byrd JC, Kisseberth WC, London CA, Muthusamy N.

Vet Comp Oncol. 2017 Sep;15(3):1115-1118. doi: 10.1111/vco.12221. Epub 2016 May 2.

10.

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model.

Saba C, Paoloni M, Mazcko C, Kisseberth W, Burton JH, Smith A, Wilson-Robles H, Allstadt S, Vail D, Henry C, Lana S, Ehrhart EJ, Charles B, Kent M, Lawrence J, Burgess K, Borgatti A, Suter S, Woods P, Gordon I, Vrignaud P, Khanna C, LeBlanc AK.

PLoS One. 2016 Feb 11;11(2):e0149194. doi: 10.1371/journal.pone.0149194. eCollection 2016.

11.

Human Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell Lines.

Clemente-Vicario F, Alvarez CE, Rowell JL, Roy S, London CA, Kisseberth WC, Lorch G.

PLoS One. 2015 Nov 11;10(11):e0142007. doi: 10.1371/journal.pone.0142007. eCollection 2015.

12.

Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma.

Brown ME, Bear MD, Rosol TJ, Premanandan C, Kisseberth WC, London CA.

BMC Vet Res. 2015 Aug 14;11:206. doi: 10.1186/s12917-015-0505-7.

13.

Comparison of high-dose intermittent and low-dose continuous oral artemisinin in dogs with naturally occurring tumors.

Hosoya K, Couto CG, London CA, Kisseberth WC, Phelps MA, Dalton JT.

J Am Anim Hosp Assoc. 2014 Nov-Dec;50(6):390-5. doi: 10.5326/JAAHA-MS-6145. Epub 2014 Sep 23.

PMID:
25251432
14.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

15.

Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology.

Fenger JM, London CA, Kisseberth WC.

ILAR J. 2014;55(1):69-85. doi: 10.1093/ilar/ilu009. Review.

PMID:
24936031
16.

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis.

Fenger JM, Bear MD, Volinia S, Lin TY, Harrington BK, London CA, Kisseberth WC.

BMC Cancer. 2014 Feb 11;14:84. doi: 10.1186/1471-2407-14-84.

17.

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.

London CA, Bernabe LF, Barnard S, Kisseberth WC, Borgatti A, Henson M, Wilson H, Jensen K, Ito D, Modiano JF, Bear MD, Pennell ML, Saint-Martin JR, McCauley D, Kauffman M, Shacham S.

PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585. eCollection 2014.

18.

Genome-wide analyses implicate 33 loci in heritable dog osteosarcoma, including regulatory variants near CDKN2A/B.

Karlsson EK, Sigurdsson S, Ivansson E, Thomas R, Elvers I, Wright J, Howald C, Tonomura N, Perloski M, Swofford R, Biagi T, Fryc S, Anderson N, Courtay-Cahen C, Youell L, Ricketts SL, Mandlebaum S, Rivera P, von Euler H, Kisseberth WC, London CA, Lander ES, Couto G, Comstock K, Starkey MP, Modiano JF, Breen M, Lindblad-Toh K.

Genome Biol. 2013 Dec 12;14(12):R132. doi: 10.1186/gb-2013-14-12-r132.

19.

Postoperative adjuvant combination therapy with doxorubicin and noncytotoxic suramin in dogs with appendicular osteosarcoma.

Alvarez FJ, Kisseberth W, Hosoya K, Lara-Garcia A, Kosarek C, Murahari S, Au JL, Wientjes MG, Couto J, Couto G.

J Am Anim Hosp Assoc. 2014 Jan-Feb;50(1):12-8. doi: 10.5326/JAAHA-MS-5958. Epub 2013 Nov 11.

PMID:
24216494
20.

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose.

Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA.

BMC Vet Res. 2013 Sep 30;9:190. doi: 10.1186/1746-6148-9-190.

21.

VAC protocol for treatment of dogs with stage III hemangiosarcoma.

Alvarez FJ, Hosoya K, Lara-Garcia A, Kisseberth W, Couto G.

J Am Anim Hosp Assoc. 2013 Nov-Dec;49(6):370-7. doi: 10.5326/JAAHA-MS-5954. Epub 2013 Sep 19.

PMID:
24051260
22.

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.

Couto JI, Bear MD, Lin J, Pennel M, Kulp SK, Kisseberth WC, London CA.

BMC Vet Res. 2012 Dec 17;8:244. doi: 10.1186/1746-6148-8-244.

23.

Molecular profiling reveals prognostically significant subtypes of canine lymphoma.

Frantz AM, Sarver AL, Ito D, Phang TL, Karimpour-Fard A, Scott MC, Valli VE, Lindblad-Toh K, Burgess KE, Husbands BD, Henson MS, Borgatti A, Kisseberth WC, Hunter LE, Breen M, O'Brien TD, Modiano JF.

Vet Pathol. 2013 Jul;50(4):693-703. doi: 10.1177/0300985812465325. Epub 2012 Nov 2.

24.

Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs.

Sherger M, Kisseberth W, London C, Olivo-Marston S, Papenfuss TL.

BMC Vet Res. 2012 Oct 31;8:209. doi: 10.1186/1746-6148-8-209.

25.

Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.

de Brito Galvao JF, Kisseberth WC, Murahari S, Sutayatram S, Chew DJ, Inpanbutr N.

Am J Vet Res. 2012 Aug;73(8):1262-72. doi: 10.2460/ajvr.73.8.1262.

PMID:
22849687
27.

Retrospective evaluation of the effectiveness of epsilon aminocaproic acid for the prevention of postamputation bleeding in retired racing Greyhounds with appendicular bone tumors: 46 cases (2003-2008).

Marín LM, Iazbik MC, Zaldivar-Lopez S, Lord LK, Stingle N, Vilar P, Lara-Garcia A, Alvarez F, Hosoya K, Nelson L, Pozzi A, Cooper E, McLoughlin MA, Ball R, Kisseberth WC, London CA, Dudley R, Dyce J, McMahon M, Lerche P, Bednarski R, Couto CG.

J Vet Emerg Crit Care (San Antonio). 2012 Jun;22(3):332-40. doi: 10.1111/j.1476-4431.2012.00735.x. Epub 2012 May 21.

PMID:
22612729
28.

Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.

Angstadt AY, Motsinger-Reif A, Thomas R, Kisseberth WC, Guillermo Couto C, Duval DL, Nielsen DM, Modiano JF, Breen M.

Genes Chromosomes Cancer. 2011 Nov;50(11):859-74. doi: 10.1002/gcc.20908. Epub 2011 Aug 11.

PMID:
21837709
29.

A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphoma.

Ito D, Endicott MM, Jubala CM, Helm KM, Burnett RC, Husbands BD, Borgatti A, Henson MS, Burgess KE, Bell JS, Kisseberth WC, Valli VE, Cutter GR, Avery AC, Hahn KA, O'Brien TD, Modiano JF.

J Vet Intern Med. 2011 Jul-Aug;25(4):890-6. doi: 10.1111/j.1939-1676.2011.0756.x.

30.

Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach.

Scott MC, Sarver AL, Gavin KJ, Thayanithy V, Getzy DM, Newman RA, Cutter GR, Lindblad-Toh K, Kisseberth WC, Hunter LE, Subramanian S, Breen M, Modiano JF.

Bone. 2011 Sep;49(3):356-67. doi: 10.1016/j.bone.2011.05.008. Epub 2011 May 15.

31.

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.

Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA.

BMC Cancer. 2011 Apr 11;11:125. doi: 10.1186/1471-2407-11-125.

32.

The novel curcumin analog FLLL32 decreases STAT3 DNA binding activity and expression, and induces apoptosis in osteosarcoma cell lines.

Fossey SL, Bear MD, Lin J, Li C, Schwartz EB, Li PK, Fuchs JR, Fenger J, Kisseberth WC, London CA.

BMC Cancer. 2011 Mar 28;11:112. doi: 10.1186/1471-2407-11-112.

33.

Development of a brain metastatic canine prostate cancer cell line.

Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, Rosol TJ.

Prostate. 2011 Sep;71(12):1251-63. doi: 10.1002/pros.21341. Epub 2011 Feb 14.

34.

Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs.

Paoloni MC, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, Vail DM, Nuckolls K, Osborne T, Yalkowsy S, Gustafson D, Yu Y, Cao L, Khanna C.

PLoS One. 2010 Jun 8;5(6):e11013. doi: 10.1371/journal.pone.0011013.

35.

AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA.

Blood. 2010 May 27;115(21):4217-25. doi: 10.1182/blood-2009-07-231985. Epub 2010 Mar 16.

36.

Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.

Hosoya K, Lord LK, Lara-Garcia A, Kisseberth WC, London CA, Couto CG.

Vet Comp Oncol. 2009 Dec;7(4):244-55. doi: 10.1111/j.1476-5829.2009.00197.x.

PMID:
19891695
37.

Characterization of STAT3 activation and expression in canine and human osteosarcoma.

Fossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC, London CA.

BMC Cancer. 2009 Mar 10;9:81. doi: 10.1186/1471-2407-9-81.

38.

NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging.

Nadella MV, Kisseberth WC, Nadella KS, Thudi NK, Thamm DH, McNiel EA, Yilmaz A, Boris-Lawrie K, Rosol TJ.

Vet Comp Oncol. 2008 Mar;6(1):39-54. doi: 10.1111/j.1476-5829.2007.00139.x.

39.

Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.

Hosoya K, Kisseberth WC, Alvarez FJ, Lara-Garcia A, Beamer G, Stromberg PC, Couto CG.

J Am Anim Hosp Assoc. 2009 Jan-Feb;45(1):14-8.

PMID:
19122059
40.

Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.

Kisseberth WC, Murahari S, London CA, Kulp SK, Chen CS.

Am J Vet Res. 2008 Jul;69(7):938-45. doi: 10.2460/ajvr.69.7.938.

PMID:
18593248
41.

Biological activity of dihydroartemisinin in canine osteosarcoma cell lines.

Hosoya K, Murahari S, Laio A, London CA, Couto CG, Kisseberth WC.

Am J Vet Res. 2008 Apr;69(4):519-26. doi: 10.2460/ajvr.69.4.519.

PMID:
18380584
42.

Phase I clinical evaluation of carboplatin in tumor-bearing cats: a Veterinary Cooperative Oncology Group study.

Kisseberth WC, Vail DM, Yaissle J, Jeglum KA, Couto CG, Ward H, Khanna C, Obradovich JE.

J Vet Intern Med. 2008 Jan-Feb;22(1):83-8. doi: 10.1111/j.1939-1676.2007.0017.x.

43.

Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.

Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Lara-Garcia A, Kosarek CE, London CA, Couto CG.

J Vet Intern Med. 2007 Nov-Dec;21(6):1355-63.

44.

Quantification of plasma DNA as a prognostic indicator in canine lymphoid neoplasia.

Schaefer DM, Forman MA, Kisseberth WC, Lehman AM, Kelbick NT, Harper P, Rush LJ.

Vet Comp Oncol. 2007 Sep;5(3):145-55. doi: 10.1111/j.1476-5829.2007.00122.x.

PMID:
19754786
45.

Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.

Fosmire SP, Thomas R, Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Smith TL, Gardner LA, Ritt MG, Bell JS, Freeman KP, Greenfield BE, Lana SE, Kisseberth WC, Helfand SC, Cutter GR, Breen M, Modiano JF.

Vet Pathol. 2007 Jul;44(4):467-78.

PMID:
17606508
46.

A novel canine lymphoma cell line: a translational and comparative model for lymphoma research.

Kisseberth WC, Nadella MV, Breen M, Thomas R, Duke SE, Murahari S, Kosarek CE, Vernau W, Avery AC, Burkhard MJ, Rosol TJ.

Leuk Res. 2007 Dec;31(12):1709-20. Epub 2007 May 29.

PMID:
17532464
47.

3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line.

Alvarez FJ, Murahari S, Couto CG, Rosol TJ, Kulp SK, Chen CS, Kisseberth WC.

Vet Comp Oncol. 2007 Mar;5(1):47-58. doi: 10.1111/j.1476-5829.2006.00117.x.

PMID:
19754801
48.

Dexamethasone, melphalan, actinomycin D, cytosine arabinoside (DMAC) protocol for dogs with relapsed lymphoma.

Alvarez FJ, Kisseberth WC, Gallant SL, Couto CG.

J Vet Intern Med. 2006 Sep-Oct;20(5):1178-83.

49.

Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers.

Kosarek CE, Hu X, Couto CG, Kisseberth WC, Green EM, Au JL, Wientjes MG.

J Vet Intern Med. 2006 Sep-Oct;20(5):1172-7.

50.

Effects of calcitriol, seocalcitol, and medium-chain triglyceride on a canine transitional cell carcinoma cell line.

Kaewsakhorn T, Kisseberth WC, Capen CC, Hayes KA, Calverley MJ, Inpanbutr N.

Anticancer Res. 2005 Jul-Aug;25(4):2689-96.

Supplemental Content

Loading ...
Support Center